Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Cancer J. 2013 Jul-Aug;19(4):311–315. doi: 10.1097/PPO.0b013e31829d5cea

Table 2.

Ongoing Trials with Novel PI3-K/Akt Inhibitors in RCC

Agent Mechanism of Action Trial
MK2206 Allosteric inhibitor of Akt A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma (NCT01239342)
GDC-0980 Pan-isoform inhibitor of PI3-K and catalytic inhibitor of mTOR A Phase II, Open Label, Randomized Study of GDC-0980 Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following VEGF-Targeted Therapy (NCT01442090)
BEZ-235 Pan-isoform inhibitor of PI3-K and catalytic inhibitor of mTOR\ A Phase 1b/2 Study of BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) (NCT01453595)